Results 191 to 200 of about 1,581,690 (305)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

When the nerve speaks first: IgG4-related disease unmasked by peripheral neuropathy. [PDF]

open access: yesFront Neurol
Zhou Y   +6 more
europepmc   +1 more source

Mixed Signals: T Cells as Architects of IgE Immunity

open access: yesImmunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Food allergen‐specific IgE can cause significant pathology, yet the pathways that generate pathogenic, high‐affinity IgE remain incompletely understood. Increasing evidence suggests that IgE responses arise from the integration of multiple, and sometimes opposing, T cell–derived cues.
Abigail L. Tierney   +3 more
wiley   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts

open access: yesImmunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles.
Sophieke Lems   +3 more
wiley   +1 more source

IgG4-Related Disease With Lung and Kidney Involvement: A Case Report. [PDF]

open access: yesCureus
Sá Lima A   +3 more
europepmc   +1 more source

The Incidence of IgG4-Related Disease in Slovenia-Single-Centre Experience. [PDF]

open access: yesBiomedicines
Hočevar A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy